Role of voglibose in prevention of type 2 diabetes in established case of impaired glucose tolerance: an observation study

Mohammed Riyaz1,*, Imran S2, Nidhisha K. Joseph3, Maryam Saba4

1Associate Professor of Medicine, Department of Medicine, MNR Medical College, Sanga Reddy, Telangana-502294, India
2Consultant Diabetologist, 3Senior Diabetic Educator Nurse, Department of Endocrinology, 4Diabetic Educator, Department of Endocrinology, Esani Diabetes & Multispeciality Centre, Tolichowki, Hyderabad, Telangana-500008, India

Received: 17 April 2015
Revised: 01 May 2015
Accepted: 08 May 2015

*Correspondence: Dr. Mohammed Riyaz,
E-mail: riyaz esi@hotmail.com

ABSTRACT

Background: The increased prevalence of type 2 diabetes mellitus is a major concern for the health providers. We have done an observation study in the diagnosed IGT patient who received α-glucosidase inhibitor (voglibose), which could prevent the development of type 2 diabetes in high-risk individuals.

Methods: This study was an observational study comprising of voglibose and placebo in individuals with impaired glucose tolerance. 66 eligible patients were on the standard diet and taking regular exercise with impaired glucose tolerance were randomly assigned to oral voglibose 0.2 mg three times a day (n=66) or placebo (n=60) in this study. Treatment was continued until participants developed type 2 diabetes (primary endpoint) or normoglycaemia (secondary endpoint).

In the final analysis, 66 registered individuals fulfilled the inclusion criteria: 36 were randomly assigned to receive voglibose and 30 placebos (two participants in the placebo group did not take their medication and were excluded).

Results: The mean duration of treatment was 48.3 weeks (SD: 36.4), i.e., 45.4 weeks (34.7) for voglibose and 51.7 weeks (37.4) for placebo. Voglibose was better than placebo (p=0.0024) in individuals treated for an average of 48.3 weeks (SD 36.4). Patients treated with voglibose had a lower risk of progression to type 2 diabetes than did those on placebo. More people in the voglibose group achieved normoglycaemia than did those in the placebo group.

Conclusion: Voglibose, in addition to lifestyle modification, can reduce the development of type 2 diabetes in high risk individuals with impaired glucose tolerance.

Keywords: Voglibose, Diabetes mellitus, IGT, Impaired glucose tolerance, Prevention

INTRODUCTION

Impaired fasting glucose (IFG), also termed as pre-diabetes. IFGs referred when the fasting blood glucose level is consistently elevated above the normal levels. This pre-diabetic state is associated with increase risk of cardiovascular events and insulin resistance, although of lesser risk than impaired glucose tolerance (IGT). IFG can progress to type 2 diabetes mellitus if lifestyle changes are not made. There is a 50% risk over 10 years of progressing to overt diabetes.

- WHO criteria: fasting plasma glucose level from 6.1 mmol/l (110 mg/dL) to 6.9 mmol/l (125 mg/dL).
- ADA criteria: fasting plasma glucose level from 5.6 mmol/L (100 mg/dL) to 6.9 mmol/L (125 mg/dL).

Impaired Glucose Tolerance (IGT) is defined as: two-hour glucose levels of 140 to 199 mg per dL (7.8 to 11.0 mmol/L)
11.0 mmol/l) on the 75-g oral glucose tolerance test (according to WHO and ADA). A patient is said to be under the condition of IGT when he/she has an immediately raised glucose level after 2 hours, but less than would qualify for type 2 diabetes mellitus. The fasting glucose may be either normal or mildly elevated.

Although type 2 diabetes has a genetic basis, evidence supports a key part played by modifiable behavioural risk factors such as obesity and physical inactivity.

The International Diabetes Federation Taskforce on Prevention and Epidemiology convened a consensus workshop in Lisbon, Portugal, recommended a three-step approach i.e.

- Identification of those people at risk,
- Measurement of the risk, and
- Appropriate intervention to prevent or delay the development of type 2 diabetes.

The European DECODE study, a meta-analysis of 13 prospective cohort studies, some in Asian individuals, reported that impaired glucose tolerance is a prognostic factor for both all-cause and cardiovascular death. Thus, impaired glucose tolerance not only increases the likelihood of developing diabetes, but also exacerbates cardiovascular pathological changes. Treatment strategies designed to slow or delay the progression of impaired glucose tolerance therefore have the potential to reduce cardiovascular morbidity and mortality, and some of the burden on health-care resources. Indeed, results of large, well designed trials have suggested that intensive diet and exercise programmes, and pharmacological intervention, help prevent or delay the development of diabetes in high-risk individuals with impaired glucose tolerance.

Diabetes is a global problem, and its prevalence in Asia is predicted to increase substantially over the next 25 years. Studies specifically involving Asian people include the Da Qing study in China, the Indian Diabetes Prevention Programme, and a Japanese lifestyle intervention trial. Until now, no active drug intervention trial in Japanese individuals with impaired glucose tolerance has been reported. We therefore investigated the effectiveness of voglibose, an α-glucosidase inhibitor that reduces diurnal insulin secretion, for prevention of the development of type 2 diabetes in Japanese patients with impaired glucose tolerance.

**METHODS**

**Study design**

This study was an observational study comprising of voglibose and placebo in individuals with impaired glucose tolerance. From November, 2013, we aimed to treat people until type 2 diabetes or normoglycaemia was diagnosed, or for at least 1 year.

**Procedure**

We recruited individuals from all socio-economic status, mainly through assessment of high-risk populations, and in particular from first-degree relatives of patients with type 1 or 2 diabetes. We screened 610 people men and women aged 30–70 years, with suspected impaired glucose tolerance for family history, blood pressure, body weight, body-mass index, routine blood chemistry (including lipid concentrations), fasting plasma glucose concentrations, and HbA1c, and did an oral glucose (75 mg) tolerance test (OGTT) during a 4-week observation. Individuals were eligible if they had a fasting plasma glucose concentration of less than 6.9 mmol/L, a 2 h plasma glucose concentration during OGTT (<7 mmol/L), and a white platelet glucose concentration of less than 6.9 mmol/L, HbA1c less than 6.5%, and at least one of the following risk factors for type 2 diabetes: high normal blood pressure (systolic ≥130 mmHg or diastolic ≥85 mmHg) or were being treated for hypertension; dyslipidaemia (concentrations of total cholesterol ≥5.7 mmol/L, triglyceride ≥1.7 mmol/L, or LDL cholesterol <1.04 mmol/L); obesity (body-mass index ≥25 kg/m²); and a family history of diabetes (in a first-degree or second-degree relative). We excluded patients with diabetes or a disease likely to impair glucose tolerance. The patients who were fitting into the inclusion criteria were only 66.

Eligible individuals were randomly allocated to voglibose 0.2 mg or an identical-looking placebo three times a day before meals. 4–8 weeks before the start of treatment, each person was given advice about appropriate nutrition and exercise programmes (interview, survey of lifestyle, and individualised guidance on future lifestyle habits based on intensity of daily activity categories) and adherence to these was assessed at each visit. The primary endpoint was the development of type 2 diabetes, which was defined as an HbA1c level of at least 6.5%, and, on two separate occasions, at least one of the following: a 2hPG of at least 11.1 mmol/L, fasting plasma glucose concentration of at least 7.8 mmol/L, or random plasma glucose concentration of at least 11.1 mmol/L. The secondary endpoint was the number of people who achieved normoglycaemia (ie, 2hPG <7.8 mmol/L and a fasting plasma glucose concentration <6.1 mmol/L). Once the primary or secondary endpoint was achieved, patients discontinued their medication (those who achieved normoglycaemia are being followed up until study completion, when their responses will be analysed).

Every 12 weeks, we measured the concentrations of fasting blood glucose, HbA1c, and blood lipids (triglycerides, total cholesterol, HDL cholesterol, and free fatty acids), did clinical laboratory tests (chemistry, haematology, and urinalysis), measured blood pressure and body weight, did compliance checks (returned tablet counts), and questioned patients about adverse effects. We did an OGTT every 24 weeks. All blood and urine analytical tests were done at a central laboratory with standard methods.
RESULTS

In the final analysis, 66 registered individuals fulfilled the inclusion criteria: 36 were randomly assigned to receive voglibose and 30 placebos (two participants in the placebo group did not take their medication and were excluded). The mean duration of treatment was 48.3 weeks (SD 36.4) for voglibose and 51.7 weeks (37.4) for placebo. Compliance with treatment was similarly high in the two treatment groups.

In the analysis, we found that voglibose was better than placebo (p=0.0024) in individuals treated for an average of 48.3 weeks (SD 36.4). Patients treated with voglibose had a lower risk of progression to type 2 diabetes than did those on placebo. More people in the voglibose group achieved normoglycaemia than did those in the placebo group.

Table 1: Adverse effects.

<table>
<thead>
<tr>
<th>Manifestation</th>
<th>Voglibose</th>
<th>Placebo</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>symptoms:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flatulence</td>
<td>11 (17%)</td>
<td>4 (7%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Abdominal distension</td>
<td>8 (13%)</td>
<td>3 (5%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>8 (13%)</td>
<td>3 (5%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Abnormal bowel sounds</td>
<td>2 (4%)</td>
<td>1 (2%)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

DISCUSSION

In our study, even though we reinforced diet and exercise programmes, individuals remained at risk of developing diabetes. Voglibose significantly reduced the risk of individuals with impaired glucose tolerance developing type 2 diabetes and significantly increased the proportion of people who achieved normoglycaemia compared with placebo. One of the potential benefits of a reduction in the progression of impaired glucose tolerance to type 2 diabetes might be a reduction in cardiovascular risk. However, a 20-year follow-up from the original Da Qing Diabetes Prevention Study showed that, although lifestyle changes could produce a long-lasting reduction in the incidence of type 2 diabetes, the effect on cardiovascular events was at best modest.

Over the past decade, numerous studies have drawn attention to the benefits of strict and individualised diet and exercise programmes in delaying the progression to type 2 diabetes. In these studies, lifestyle modification reduced the risk of type 2 diabetes by 42% over 6 years (p<0.005) in a Chinese cohort, by 58% over 4 years (p<0.001) in Finnish patients, and by 58% over 2.8 years in a US study. Lifestyle modification thus represents a mainstay of medical care for individuals with impaired glucose tolerance. Pharmacological approaches have also been investigated as a means of delaying the onset of type 2 diabetes and drugs such as metformin, acarbose, voglibose have all shown some ability to delay or prevent the progression of impaired glucose tolerance to type 2 diabetes. In the Study TO Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM), the α-glucosidase inhibitor acarbose reduced the risk of progression to diabetes by 25% over 3-3 years compared with placebo. This result was achieved in people with impaired glucose tolerance that was given advice on diet and exercise. Similarly, the Diabetes Prevention Program Research Group reported that metformin reduced the relative risk of people with impaired glucose tolerance developing diabetes by 31% over 2.8 years. Defects in the secretion or action of insulin, or both, are the two common abnormalities leading to the development of type 2 diabetes. If we intervene and protects the pancreatic β cells by diet modification or pharmacotherapy we could help in preventing or delaying the progression of the disease. Results with voglibose show that it reduces diurnal insulin secretion through improvement of postprandial hyperglycaemia, and these changes should reduce the stress on overworked β cells. In our observational study, 2hPG concentrations fluctuated at a lower level in the voglibose group than in the placebo group between 24 weeks and 30 weeks as indicated by lower HbA1c levels during this period. Assessments beyond this time point are not meaningful because of the small numbers of patients.

Voglibose significantly improved glucose tolerance, in terms of delayed disease progression and in the number of patients who achieved normoglycaemia. Thus, long-term prophylaxis with this α-glucosidase inhibitor in high-risk individuals with impaired glucose tolerance could provide a pharmacological option, along with lifestyle modification, to help reduce the burden of type 2 diabetes.

ACKNOWLEDGEMENTS

Authors would like to acknowledge Esani Diabetes and Multispecialty Research Centre for granting the permission to do this study.

Funding: Nil
Conflict of interest: Nil
Ethical approval: Approved from ethics committee of EDSC

REFERENCES


DOI: 10.18203/2320-6012.ijrms20150166